Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.
Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats ...
Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.'s latest push into healthcare will disrupt Hims & Hers' business.
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
The tech company’s prices appear set to undercut the long list of competing telehealth companies that rely on aggressive ...
Hims & Hers (HIMS) is down -17.7%, or -$4.88 to $22.72. Published first on TheFly – the ultimate source for real-time, ...
BofA lowered its rating of Hims & Hers (HIMS) to underperform from buy, citing Amazon’s (AMZN) push into the hair loss and ...
Stocktwits on MSN7h
Hims & Hers Stock’s Retail Army Brushes Off Amazon Medical One’s Rival Service Even As Citi Sees ThreatShares of Hims & Hers ($HIMS) plummeted nearly 15% on Thursday after Amazon.com, Inc. ($AMZN) launched its new Amazon One ...
In response to the FDA’s shortage decision, Hims & Hers is launching a new GLP-1 tracker, allowing patients to self-identify, provide ...
Other treatment plans include medication for motion sickness and eyelash growth. The move puts Amazon in direct competition ...
Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com launched a rival service that offers upfront pricing ...
(Irwin, 11/13) Yahoo Finance: Hims & Hers Launches GLP-1 Tracker In Response To FDA's Shortage Decision Hims & Hers is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback